Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines

NCT04875676 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Norovirus Infections

Interventions

BIOLOGICAL: VXA-G1.1-NN

Sponsor

Vaxart